Akeso

This study tests two experimental drugs (AK112 and cadonilimab) plus standard chemotherapy as a first treatment for people with stage IV pancreatic cancer. About 110 adults aged 18-75 who have not had prior treatment will participate. The goal is to see if the combination is safe…

This study tests two experimental drugs (AK112 and AK117) given together to people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination is safe and can shrink or control the tumors. About 154 adults aged 18 to 75 are taking…

This study tests two experimental drugs, AK112 and AK117, alone or together, in people with metastatic colorectal cancer that cannot be removed by surgery. The goal is to see if these drugs can shrink tumors or slow the disease. About 254 participants will be enrolled, and the st…

This study tests whether a new drug called AK112, when combined with standard chemotherapy, works better than another drug (durvalumab) plus the same chemo for people with advanced bile duct cancer that cannot be removed by surgery. About 682 adults with good overall health will …

This study tests a new drug called AK112 combined with standard chemotherapy in people with a specific type of advanced lung cancer (non-squamous non-small cell) that has a mutation in the EGFR gene and has stopped responding to initial targeted therapy. About 322 participants wi…

This early-stage trial tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose, while also seeing if the combination can shrink tumors o…

This study tests two immunotherapy drugs (AK112 and AK104) together, with or without chemotherapy, in people with advanced non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination is safe and helps shrink tumors or slow the disease. Abo…

This study tests two experimental drugs, AK119 and AK112, alone or with chemotherapy, in 170 adults with a specific type of colorectal cancer (pMMR/MSS) that often doesn't respond well to standard treatments. The goal is to see if these combinations can shrink tumors or slow the …

This study tests a new drug called AK112 combined with chemotherapy in 265 adults with advanced non-small cell lung cancer (NSCLC) that has spread. The goal is to see if the combo can shrink tumors and delay cancer growth. Participants must have stage IIIB/C or IV NSCLC and be in…

This study tests whether adding two experimental drugs (AK117 and AK112) to standard chemotherapy can shrink tumors in people with advanced triple-negative breast cancer that hasn't been treated before. About 120 participants will receive the combination and be monitored for resp…

This study tests a new drug called AK112, given alone or with chemotherapy, before and after surgery for people with early-stage non-small cell lung cancer that can be removed. The goal is to see if the drug helps shrink tumors and improve outcomes. About 90 adults aged 18-75 wit…

This phase 3 trial tests whether a new drug called AK112 works better than the standard immunotherapy pembrolizumab for people with advanced non-small cell lung cancer that has a specific marker (PD-L1). About 398 participants with stage IIIB/C or IV lung cancer will receive eith…

This phase 3 trial tests whether adding the drug AK104 to standard chemotherapy (with or without bevacizumab) helps people with advanced cervical cancer live longer without their disease getting worse. About 445 women whose cancer has spread or returned and cannot be cured by sur…

This study checks whether AK112, an experimental antibody drug, behaves the same in the body when made at a new factory versus the original one. It involves 108 healthy men aged 18-45. The goal is to compare drug levels and safety, not to treat any disease.